|  |  |
| --- | --- |
| Type of study | Select sections that best describes your study by adding comments |
| THERAPY |  |
| PREVENTION |  |
| DIAGNOSIS |  |
| ETIOLOGY |  |
| COST ANALYSIS |  |

|  |  |
| --- | --- |
| COMPONENTS OF PICO | YOUR QUESTION? |
| P- patient or population |  |
| I –intervention , exposure , prognostic factor |  |
| C-comparison ( standard therapy , gold standard) |  |
| O-outcomes and variables of interest (reduced morbidity, accuracy etc.) |  |
| The well-built clinical question should include PICO format, (please see examples below) | |

Some examples to consider:

***THERAPY***

In children with IBD (P), what is the effect of anti-TNF’s (I) on CS free sustained remission and mucosal healing rates (O) compared with IL12/23 inhibitors (C) within 2 years of diagnosis (T)?

***PREVENTION***

For children with UC (P) does the use of ASA co-therapy with anti-TNF therapy (I) reduce the future risk of relapse (O) compared with anti-TNF monotherapy (C)?

***DIAGNOSIS/PROGNOSIS***

Does early use of anti-TNF (I) influence development of complicating Crohn’s disease and surgical resection (O) in patients who have inflammatory Crohn’s disease at diagnosis (P) over 5 years (T)?

In children with ileal vs. colonic CD (P), how does early anti-TNF agent (I) compared to late anti-TNF use (C) influence development of complicating CD (O) over 5 years (T)?

***ETIOLOGY***

Are children (P) who have celiac disease in addition to IBD (I) compared with those IBD without celiac disease (C) at risk for/of poor response to anti-TNF therapy (O) over 5 years(T)?